New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Tirzepatide is a dual GLP-1 and GIP receptor agonist ... Section 5 – User Journey and Market Tone Public discussions around GLP-1 weight management increasingly focus on the patient journey - from ...

Why GLP-1 pills could be a game-changer. Several oral GLP-1 pills are in late-stage development — and they’re getting closer to hitting the market. They work in a similar way as injectable GLP-1s.

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

More than 2% of adult patients now take a GLP-1 drug to treat overweight or obesity, according to newly released FAIR Health data, with much of the increase occurring over the past few years. Among ...

GLP-1 medications have become game changers for people trying to lose weight, but bariatric surgery is still superior when it comes to total and lasting weight loss, a new study has found.